Cohance Lifesciences Q1 Review: Brokerages Split After Earnings Slump — Check Potential Upside, Target Price

Macquarie retained its Outperform rating on Cohance Lifesciences despite a weaker-than-expected June quarter, while Jefferies maintained Underperform as sales declines across businesses pushed EBITDA close to break-even.